- Home
- ROOT vs NGNE Comparison
ROOT vs NGNE Comparison
Compare ROOT & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROOT | NGNE |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 889.5M | 744.9M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ROOT | NGNE |
|---|---|---|
| Price | $52.79 | $23.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $57.00 | ★ $77.88 |
| AVG Volume (30 Days) | 156.7K | ★ 294.2K |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.96 | 0.93 |
| EPS | ★ 3.58 | N/A |
| Revenue | ★ $1,517,100,000.00 | N/A |
| Revenue This Year | $1.88 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.04 | ★ N/A |
| Revenue Growth | ★ 28.95 | N/A |
| 52 Week Low | $40.91 | $15.93 |
| 52 Week High | $91.00 | $43.66 |
Technical Indicators
Market Signals| Indicator | ROOT | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 60.40 | 37.52 |
| Support Level | $51.00 | $18.68 |
| Resistance Level | $58.38 | $29.16 |
| Average True Range (ATR) | 1.59 | 2.10 |
| MACD | 0.79 | 0.32 |
| Stochastic Oscillator | 85.26 | 28.15 |
Price Performance
Historical ComparisonAbout ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.